Investing.com - Biofrontera reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Biofrontera announced earnings per share of $-0.11 on revenue of $4.3M. Analysts polled by Investing.com anticipated EPS of $-0.29 on revenue of $4.31M.
Biofrontera shares are up 7% from the beginning of the year, still down 93.23% from its 52 week high of $14.63 set on December 21, 2021.
Biofrontera shares gained 7.07% in pre-market trade following the report.
Biofrontera follows other major Healthcare sector earnings this month
Biofrontera's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar